COVID-19-related mortality and hospital admissions in the VIVALDI study cohort: October 2020 to March 2023

• Published in: The Journal of hospital infection Vol. 143; pp. 105 - 112
• Main Authors: Stirrup, O., Krutikov, M., Azmi, B., Monakhov, I., Hayward, A., Copas, A., Shallcross, L.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.01.2024; W.B. Saunders For The Hospital Infection Society
• Subjects: Care homes; COVID-19; Infection fatality ratio; Infection hospitalization ratio; SARS-CoV-2; COVID-19; SARS-CoV-2; Infection hospitalization ratio; Infection fatality ratio; Care homes
• ISSN: 0195-6701; 1532-2939
• DOI: 10.1016/j.jhin.2023.10.021

Long-term-care facilities (LTCFs) were heavily affected by COVID-19 early in the pandemic, but the impact of the virus has reduced over time with vaccination campaigns and build-up of immunity from prior infection. To evaluate the mortality and hospital admissions associated with SARS-CoV-2 in LTCFs in England over the course of the VIVALDI study, from October 2020 to March 2023. We included residents aged ≥65 years from participating LTCFs who had available follow-up time within the analysis period. We calculated incidence rates (IRs) of COVID-19-linked mortality and hospital admissions per calendar quarter, along with infection fatality ratios (IFRs, within 28 days) and infection hospitalization ratios (IHRs, within 14 days) following positive SARS-CoV-2 test. A total of 26,286 residents were included, with at least one positive test for SARS-CoV-2 in 8513 (32.4%). The IR of COVID-19-related mortality peaked in the first quarter (Q1) of 2021 at 0.47 per 1000 person-days (1 kpd) (around a third of all deaths), in comparison with 0.10 per 1 kpd for Q1 2023 which had a similar IR of SARS-CoV-2 infections. There was a fall in observed IFR for SARS-CoV-2 infections from 24.9% to 6.7% between these periods, with a fall in IHR from 12.1% to 8.8%. The population had high overall IRs for mortality for each quarter evaluated, corresponding to annual mortality probability of 28.8–41.3%. Standardized real-time monitoring of hospitalization and mortality following infection in LTCFs could inform policy on the need for non-pharmaceutical interventions to prevent transmission.